TY - JOUR AU - Kashif Rauf , Adnan Afzal , Fawad Hussain , Sadia Mohammad Azam Khan , Sikander Hayat Warraich , Kashif Zaheer, Kashif Rauf , Adnan Afzal , Fawad Hussain , Sadia Mohammad Azam Khan , Sikander Hayat Warraich , Kashif Zaheer PY - 2020/12/30 Y2 - 2024/03/28 TI - A comparative study to evaluate effects on HCV-RNA-PCR by current oral anti-viral therapy with Sofosbuvir and Daclatasvir in Hepatitis C patients with and without Diabetes Melitis in Pakistan JF - Journal of Rawalpindi Medical College JA - JRMC VL - 24 IS - 4 SE - Articles DO - 10.37939/jrmc.v24i4.1502 UR - http://journalrmc.com/index.php/JRMC/article/view/1502 SP - AB - <p><strong>Objective:</strong> To compare the effects of antiviral therapy such as sofosbuvir and daclatasvir in HCV patients which were diagnosed by HCV-RNA PCR without Diabetes Melitis.</p><p><strong>Study Design:<em>&nbsp; </em></strong>Cross-sectional comparative study</p><p><strong>Inclusion Criteria: </strong>HCV Positive patients after PCR test conformation between 20-75 years age.</p><p><strong>Methodology:</strong> In this cross-sectional analysis total of 100 Hepatitis c infected patients selected, Sofosbuvir plus Daclatasvir treatment given for 03 months period. Different parameters were recorded<em> such as </em>Total Bilirubin, Direct Bilirubin, Indirect Bilirubin, Hb levels, Serum ALT levels, and Serum ALP level. The statistical relation of the mentioned variables was analyzed through SPSS version 15.</p><p><strong>Results: </strong>Out of a total of 100 patients, 47% (47) were males, 53% (53) were females, 44% (44) patients had a history of prior interferon therapy, 23% (23) patients were having low hemoglobin levels before starting treatment. Both groups completed oral antiviral treatment for 12 weeks &amp; resulting data showed the equality of treatment on group B and group A as no decrease in hemoglobin (p=0.799), ALT normalization (p=1.000) &amp; no rise in serum bilirubin (p=0.817) during 1st month of treatment was noted in both groups while the SVR noted of both groups also showed no significant difference to each other i.e. 92% &amp; 94 % (p=0.696).</p><p><strong>Conclusion:</strong>&nbsp; This study concluded to monitor the anti-viral drug response against HCV patients.</p> ER -